Received Oct 13, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | — |
positive lab test for Cov-Sars2; This non-serious case was reported by a consumer via call center representative and described the occurrence of sars-cov-2 test positive in a female patient who received DTPa (Reduced antigen) (Boostrix) for prophylaxis. In JUL-2025, the patient received Boostrix. In AUG-2025, less than 2 months after receiving Boostrix, the patient experienced sars-cov-2 test positive (Verbatim: positive lab test for Cov-Sars2). The outcome of the sars-cov-2 test positive was unknown. The reporter considered the sars-cov-2 test positive to be possibly related to Boostrix. The company considered the sars-cov-2 test positive to be possibly related to Boostrix. Additional Information: GSK Receipt Date: 16-SEP-2025 Reporter stated that she had received Boostrix in July 2025. In August, they had both undergone a blood test, which returned positive for SARS-CoV-2 antigen. She denied having received a COVID-19 vaccine or ever having had a COVID-19 infection. She believed that the Boostrix vaccination had caused the lab result, and her daughter's doctor had reinforced this belief, stating that Boostrix was made with mRNA added. She further stated that both she and the pediatrician believed company was adding mRNA to its vaccines in secret. This case is linked with US2025119120, reported by same reporter.; Sender's Comments: US-GSK-US2025119120:Same reporter/Different patient
Test Date: 202508; Test Name: positive lab test for Cov-Sars2; Result Unstructured Data: (Test Result:Positive,Unit:unknown,Normal Low:,Normal High:)